New trials, publications, preprints and grants on this target, month by month.
Trial
A Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Advanced/Metastatic or Surgically Unresectable Cholangiocarcinoma With FGFR2 Fusion or Rearrangements After at Least 1 Prior Line of Systemic Therapy
15 Dec 2026· PHASE2 · NOT_YET_RECRUITING· CTGOV
Trial
A Study of Vepugratinib (LY3866288) in Adults With Non-Muscle Invasive Bladder Cancer and Upper Tract Urothelial Cancer
1 Dec 2026· PHASE2 · NOT_YET_RECRUITING· CTGOV
Trial
Efficacy and Safety of 3D185 Monotherapy in Subjects With Previously Treated Locally Advanced or Metastatic Cholangiocarcinoma
1 Dec 2026· PHASE2 · NOT_YET_RECRUITING· CTGOV
Publication
Retraction Note: Circular RNA hsa_circ_0068871 regulates FGFR3 expression and activates STAT3 by targeting miR-181a-5p to promote bladder cancer progression.
5 Nov 2026· Journal of experimental & clinical cancer research : CR· PUBMED
Publication
Modulation of Alzheimer's disease pathogenesis by the FGF-FGFR axis: therapeutic implications and translational perspectives.
4 Nov 2026· Molecular biology reports· PUBMED
Publication
FGFR1-driven brachyury promotes endothelial-like differentiation of glioblastoma stem cells via SOX2/ZEB1/YAP1 signaling pathways.
3 Nov 2026· Cellular signalling· PUBMED
Publication
A novel preclinical platform to study FGFR2 fusion-driven cholangiocarcinoma☆.
3 Nov 2026· JHEP reports : innovation in hepatology· PUBMED
Publication
Futibatinib as a bridge to transplantation and post-transplant maintenance in blast-phase MLN-ZMYM2::FGFR1.
2 Nov 2026· Journal of hematology & oncology· PUBMED
Publication
Seven-year natural history of FGFR3::TACC3-GBM.
2 Nov 2026· Journal of neuropathology and experimental neurology· PUBMED
Publication
First-line pemigatinib in a myeloid/lymphoid neoplasm with FGFR1 rearrangement: shifting the current treatment paradigm.
2 Nov 2026· Leukemia & lymphoma· PUBMED
Trial
Alternating Chemo-immunotherapy and FGFR Inhibitor for FGFR-positive Biliary or Cholangiocarcinoma
1 Nov 2026· PHASE2 · RECRUITING· CTGOV
Publication
Precision oncology needs precision trial design: lessons from FGFR2-rearranged cholangiocarcinoma.
1 Nov 2026· Nature reviews. Clinical oncology· PUBMED
Publication
[Corrigendum] Combination of the FGFR4 inhibitor PD173074 and 5‑fluorouracil reduces proliferation and promotes apoptosis in gastric cancer.
30 Oct 2026· Oncology reports· PUBMED
Publication
Structure-guided design and optimization of 3-amino-pyrazine-2-oxadiazole derivatives as novel FGFR2 inhibitors.
30 Oct 2026· European journal of medicinal chemistry· PUBMED
Publication
FGFR Alterations in Bladder Cancer-From Molecular Pathogenesis to Precision Oncology.
29 Oct 2026· JAMA oncology· PUBMED
Publication
A pivotal Phase 2 study of derazantinib for previously-treated, locally advanced or metastatic cholangiocarcinoma with FGFR2 aberrations: FIDES-01.
27 Oct 2026· Hepatology (Baltimore, Md.)· PUBMED
Publication
Evaluation of FGFR2, VEGFA, and MMP1 gene variants for ovarian cancer susceptibility among South Indian women: a hospital-based case-control study.
25 Oct 2026· Molecular biology reports· PUBMED
Publication
Saving the Capillaries: FGFR1/KLB and MFG-E8 in Diabetic Hearts.
22 Oct 2026· Circulation research· PUBMED
Publication
Combining DR5 activation with FGFR1 and VEGFR2 inhibition via an engineered TRAIL-based multimodal fusion protein for dual antitumor and antivascular activity in gastric and colorectal cancer models.
21 Oct 2026· Journal of drug targeting· PUBMED
Publication
FGFR 1-3 Alteration Frequency in Muscle-Invasive Urothelial Bladder Cancer and Its Effect on Prognosis.
20 Oct 2026· Medicina (Kaunas, Lithuania)· PUBMED
Publication
Phase 2 study of fazpilodemab, a FGFR1/Klothoβ agonist, in metabolic dysfunction-associated steatohepatitis (MASH).
17 Oct 2026· JHEP reports : innovation in hepatology· PUBMED
Publication
FDA Approval Summary: Erdafitinib for FGFR3-Altered Locally Advanced or Metastatic Urothelial Carcinoma.
15 Oct 2026· Clinical cancer research : an official journal of the American Association for Cancer Research· PUBMED
Publication
Integrated Analysis of the αKlotho-FGF23-FGFR Genetic Axis Reveals Determinants of Cardiovascular Risk in Chronic Kidney Disease.
14 Oct 2026· American journal of nephrology· PUBMED
Publication
FGFR pathway inhibition enhances PD-1 blockade and modulates antitumor immunity in colorectal cancer models.
13 Oct 2026· BMC cancer· PUBMED
Publication
[Pathogenic mechanisms and targeted therapeutic advances of the FGF/FGFR signaling pathway in hematological malignancies].
12 Oct 2026· Zhejiang da xue xue bao. Yi xue ban = Journal of Zhejiang University. Medical sciences· PUBMED
Publication
pH-Responsive Erdafitinib Liposomes with FGFR3 Targeting for Intravesical Bladder Cancer Therapy.
11 Oct 2026· International journal of molecular sciences· PUBMED
Publication
Acute monocytic leukemia with t(8;22)(p11;q11)/BCR::FGFR1, trisomy 8, and concurrent RUNX1/STAG2 mutations: A rare case report and literature review.
10 Oct 2026· Leukemia research reports· PUBMED
Publication
HOOK3::FGFR1 Fusion in a Background of FGFR1 Amplification in Childhood B-Cell Acute Lymphoblastic Leukemia.
10 Oct 2026· Pediatric blood & cancer· PUBMED
Publication
When the standard changes during the trial: Reflections on targeted therapy in FGFR2-rearranged cholangiocarcinoma.
9 Oct 2026· Med (New York, N.Y.)· PUBMED
Publication
FIND: a phase-II study to evaluate the efficacy and safety of erdafitinib in FGFR-altered NSCLC.
8 Oct 2026· Clinical cancer research : an official journal of the American Association for Cancer Research· PUBMED